1913

Development and optimization of venlafaxine hydrochloride floating microspheres using response surface plots

The current study deals with the development of floating microspheres of venlafaxine hydrochloride. This drug is known as a serotonin-norepinephrine reuptake inhibitor and used to treat depression. Due to the short elimination half life of 4-5 h, the drug has to be administred 2-3 times in a day to maintain the plasma concentration. Thus an attempt was made to decrease the dosing frequency. The microspheres were prepared by non-aqueous solvent evaporation method. The microspheres were evaluated for particle size and morphology using a photomicroscope and scanning electron microscopy, respectively. The incorporation efficiency of microspheres of batch F2 and F6 showed entrapment of 60.6% and 57.2%, respectively. The mean diameters of particles for all batches were found in the range of 226.15 ± 24.37 to 283.37 ± 21.56 μm. The Fourier transform infrared spectroscopy revealed absence of any drug - polymer interactions. The microsphers remained buoyant for more than 12 h. The drug release from developed microspheres followed Fickian diffusion with swelling. The results suggested that the developed floating microspheres containing venlafaxine hydrochloride could enhance drug entrapment efficiency, reduce the initial burst release and modulate the drug release.

PDF

___

[1] Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006; 7(2): 137-151.

[2] Nestler EJ, Barrot M, DiLeone RJ, Eisch AJ, Gold SJ, Monteggia LM. Neurobiology of depression. Neuron. 2002; 34(1): 13-25.

[3] Awasthi R, Kulkarni GT, Ramana MV, Pinto TJA, Kikuchi IS, Ghisleni DDM, Braga MS, Dua K, Bank PD. Dual crosslinked alginate-pectin network as sustained release matrix for repaglinide. Int J Biol Macromol. 2017; 97: 721- 732.

[4] Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D, Kulkarni GT. Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems. Drug Deliv. 2011; 18(2): 97-110.

[5] Awasthi R, Kulkarni GT. Decades of research in drug targeting to the upper gastrointestinal tract using gastroretention technology: Where do we stand?. Drug Deliv. 2016; 23(2): 378-394.

[6] Blier P, Saint-André E, Hébert C, de Montigny C, Lavoie N, Debonnel G. Effects of different doses of venlafaxine on serotonin and norepinephrine reuptake in healthy volunteers. Int J Neuropsychopharmacol. 2007; 10(1): 41-50.

[7] Holliday SM, Benfield P. Venlafaxine: a review of its pharmacology and therapeutic potential in depression. Drugs. 1995; 49(2): 280-294.

[8] Omprakash B, Ajay S, Santosh G, Amin P. Formulation development of venlafaxine hydrochloride extended release tablet and in vitro characterizations. Int J PharmTech Res. 2012; 4(4): 1777-1784.

[9] Fentie M, Belete A, Gebre-Mariam T. Formulation of sustained release floating microspheres of furosemide from ethylcellulose and hydroxypropyl methylcellulose polymer blends. Nanomed Nanotechnol. 2015; 6: 1-5.

[10] Prajapati ST, Patel LD, Patel DM. Gastric floating matrix tablets: design and optimization using combination of polymers. Acta Pharm. 2008; 58(2): 221-229.

[11] Li Z, Xu H, Li S, Li Q, Zhang W, Ye T, Yang X, Pan W. A novel gastro-floating multiparticulate system for dipyridamole (dip) based on a porous and low-density matrix core: In vitro and in vivo evaluation. Int J Pharm. 2014; 461: 540-548.

[12] Awasthi R, Kulkarni GT. Development and characterization of amoxicillin loaded floating microballoons for the treatment of Helicobacter pylori induced gastric ulcer. Asian J Pharm Sci. 2013; 8(3): 174-180.

[13] Awasthi R, Kulkarni GT. Development of novel gastroretentive floating particulate drug delivery system of gliclazide. Curr Drug Deliv. 2012; 9(5): 437-451.

[14] Eberle VA, Schoelkopf J, Gane P, Alles R, Huwyle J, Puchkov M. Floating gastroretentive drug delivery systems: comparison of experimental and simulated dissolution profiles and floatation behavior. Eur J Pharm Sci. 2014; 58: 34- 43.

[15] Awasthi R, Kulkarni GT. Development of novel gastroretentive drug delivery system of gliclazide: Hollow beads. Drug Dev Ind Pharm. 2014; 40(3): 398-408.

[16] Stepensky D, Friedman M, Sroar W, Raz I, Hoffman A. Formulation of controlled release dosage forms for metformin containing methocel K100M. J Control Release. 2011; 71: 107-115.

[17] Samani MS, Montaseri H, Kazemi A. Effects of polymer blends on the in vitro release profile of diclofenac sodium. Eur J Pharm Biopharm. 2003; 55: 351-355

[18] Christoper GVP, Raghavan CV, Siddharth K, Kumar MSS, Prasad RH. Formulation and optimization of coated PLGA – zidovudine nanoparticles using factorial design and in vitro-in vivo evaluations to determine brain targeting efficiency. Saudi Pharm J. 2014; 22: 133–140.

[19] Awasthi R, Kulkarni GT, Pawar VK, Garg G. Optimization studies on gastroretentive floating system using response surface methodology. AAPS PharmSciTech. 2012; 13(1): 85-94.